Lipid and inflammatory biomarker profiles in early insulin resistance

Acta Diabetologica

Volumn 53, Issue 6, 2016, Pages 905-913

  Marcelino Rodríguez, Itahisa ^a,b   Oliva García, José ^a   Alemán Sánchez, José Juan ^a,b,c   Almeida González, Delia ^a,b   Domínguez Coello, Santiago ^b,c   Brito Díaz, Buenaventura ^a,c   Gannar, Fadoua ^d   Rodríguez Pérez, María del Cristo ^a,c   Elosua, Roberto ^b,e   Cabrera de León, Antonio ^a,f  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Primary Care Authority   (Spain)

^d Struggle and Prevention   (Tunisia)

^e INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^f UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Biomarkers; C peptide; Epidemiology; Insulin resistance; Population based studies

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TRIACYLGLYCEROL; ADIPOCYTOKINE; GLUCOSE BLOOD LEVEL;

ABDOMINAL OBESITY; ADULT; AGE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ANALYSIS; BLOOD; METABOLIC SYNDROME X; METABOLISM; ONSET AGE; PROTECTION; RISK FACTOR; SPAIN;

ADIPOKINES; ADULT; AGE OF ONSET; AGED; BIOMARKERS; BLOOD GLUCOSE; C-PEPTIDE; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTECTIVE FACTORS; RISK FACTORS; SPAIN; TRIGLYCERIDES;

EID: 84978689345     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-016-0885-6     Document Type: Article

References (32)

1. Pajvani UB, Accili D (2015) The new biology of diabetes. Diabetologia 58:2459–2468
2. Muniyappa R, Madan R, Quon MJ (2000) Assessing insulin sensitivity and resistance in humans. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al. (eds) NCBI Bookshelf. Endotext [Internet]. http://www.ncbi.nlm.nih.gov/books/NBK278954. Last Update: 2 Feb 2015
3. Weyer C, Tataranni PA, Bogardus C et al(2001) Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24:89–94
4. Tabak AG, Jokela M, Akbaraly TN et al (2009) Trajectories of glycemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373:2215–2221
5. Shulman GI (2014) Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 371:1131–1141
6. Samuel VT, Shulman GI (2016) The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 126:12–22
7. Khodabandehloo H, Gorgani-Firuzjaee S, Panahi G, Meshkani R (2016) Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction. Transl Res 167:228–256
8. Cersosimo E, DeFronzo RA (2006) Insulin resistance and endothelial dysfunction: the road map for cardiovascular diseases. Diabetes Metab Res Rev 22:423–436
9. Zhan Y, Tang Z, Yu J (2014) Serum ferritin, diabetes, diabetes control, and insulin resistance. Acta Diabetol 51:991–998
10. Kharroubi I, Ladriere L, Cardozo AK et al (2004) Free fatty acids and cytokines induce pancreatic beta cell apoptosis by different mechanisms: role of NF-kappa B and endoplasmic reticulum stress. Endocrinology 145:5087–5096
11. Moran A, Steffen LM, Jacobs DR Jr et al (2005) Relation of C-reactive protein to insulin resistance and cardiovascular risk factors in youth. Diabetes Care 28:1763–1768
12. Kajimoto Y, Matsuoka T, Kaneto H et al (1999) Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells. Diabetologia 42:1417–1424
13. Daniele G, Guardado-Mendoza R, Winnier D et al (2014) The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51:123–131
14. Nwaneri C, Cooper H, Bowen-Jones D (2013) Screening for type 2 diabetes and population mortality over 10 years. Lancet 381:901–912
15. Salazar MR, Carbajal HA, Espeche WG et al (2016) Insulin resistance: the linchpin between prediabetes and cardiovascular disease. Diabetes Vasc Dis Res 13:157–163
16. Ariel D, Reaven G (2014) Modulation of coronary heart disease risk by insulin resistance in subjects with normal glucose tolerance or prediabetes. Acta Diabetol 51:1033–1039
17. Cabrera de León A, Oliva García JG, Marcelino Rodríguez I et al (2015) C-peptide as a risk factor of coronary artery disease in the general population. Diabetes Vasc Dis Res 12:199–207
18. Cabrera de León A, Rodríguez Pérez MC, Almeida González D et al (2008) Presentation of the “CDC de Canarias” cohort: objectives, design and preliminary results. Rev Esp Salud Publica 82:519–534
19. Fernández-Bergés D, Consuegra-Sánchez L, Peñafiel J et al (2014) Perfil inflamatorio y metabólico. Estudio DARIOS Inflamatorio. Rev Esp Cardiol (Engl Ed) 67:624–631
20. Ashwell M, Gunn P, Gibson S (2012) Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev 13:275–286
21. Bo S, Gentile L, Castiglione A et al (2012) C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up. Eur J Endocrinol 167:173–180
22. Kim ST, Kim BJ, Lim DM et al (2011) Basal C-peptide level as a surrogate marker of subclinical atherosclerosis in type 2 diabetic patients. Diabetes Metab J 35:41–49
23. Marx N, Silbernagel G, Brandenburg V et al (2013) C-peptide levels are associated with mortality and cardiovascular mortality in patients undergoing angiography: the LURIC study. Diabetes Care 36:708–714
24. Marx N, Walcher D, Raichle C et al (2004) C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol 24:540–545
25. Kappert K, Meyborg H, Clemenz M et al (2008) Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistance. Biochem Biophys Res Commun 365:503–508
26. Kadowaki T, Yamauchi T, Kubota N et al (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792
27. Schwartz DR, Lazar MA (2011) Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 22:259–265
28. Iqbal N, Seshadri P, Stern L et al (2005) Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci 9:161–165
29. Coello Domínguez S, Cabrera de León A, Almeida González D et al (2008) Inverse association between serum resistin and insulin resistance in humans. Diabetes Res Clin Pract 82:256–261
30. Abbasi F, Okeke Q, Reaven GM (2014) Evaluation of fasting plasma insulin concentration as an estimate of insulin action in nondiabetic individuals: comparison with the homeostasis model assessment of insulin resistance (HOMA-IR). Acta Diabetol 51:193–197
31. Noctor E, Crowe C, Carmody LA et al (2015) ATLANTIC-DIP: prevalence of metabolic syndrome and insulin resistance in women with previous gestational diabetes mellitus by International Association of Diabetes in Pregnancy Study Groups criteria. Acta Diabetol 52:153–160
32. Hivert MF, Christophi CA, Franks PW et al (2016) Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in diabetes prevention program participants. Diabetes 65:520–526